64:666-674.Necessary cookies are absolutely essential for the website to function properly. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Lincolnshire, Il: Melinta Therapeutics, Inc. JAccessed: : October 2019.īaxdela (delafloxacin). Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia (DEFINE-CABP). Oral lefamulin is safe and effective in the treatment of adults with community-acquired bacterial pneumonia (CABP): Results of lefamulin evaluation against pneumonia (LEAP 2) study (abstract LB6). 2019 Feb 4.Īlexander E, Goldberg L, et al. Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial. 31(3):602-12.įile TM Jr, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Emergency management of community-acquired bacterial pneumonia: what is new since the 2007 Infectious Diseases Society of America/American Thoracic Society guidelines. Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization. Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors. 200 (7):e45-e67.ĭartois N, Cooper CA, Castaing N, Gandjini H, Sarkozy D. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Philadelphia, Pa: Churchill Livingstone 2010. Principles and Practice of Infectious Diseases. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. What is the role of delafloxacin (Baxdela) in the empiric treatment of community-acquired pneumonia (CAP)? What is the role of lefamulin (Xenleta) in the treatment of community-acquired pneumonia (CAP)? What is the role of tigecycline in the treatment of community-acquired pneumonia (CAP)? What is the empiric therapy regimen for patients with community-acquired pneumonia (CAP) in the ICU?Īre there any updates to clinical guidelines? What is the inpatient empiric therapy regimen of community-acquired pneumonia (CAP)? What is the outpatient empiric therapy regimen for patients with community-acquired pneumonia (CAP) who have comorbidities or antibiotic use in the last 3 months? What is the initial outpatient empiric therapy regimen for community-acquired pneumonia (CAP)? What is the role of empiric therapy in the treatment of community-acquired pneumonia? What causes community-acquired pneumonia (CAP)? What is community-acquired pneumonia (CAP)? Pseudomonas aeruginosa is a cause of CAP in patients with bronchiectasis or cystic fibrosis. Staphylococcal aureus may cause CAP in patients with influenza. Aspiration pneumonia is the only form of CAP typically caused by polymicrobic infection (eg, aerobic/anaerobic oral organisms). Less commonly, CAP results from secondary bacteremia from a distant source, such as Escherichia coli urinary tract infection and/or bacteremia. Typical bacterial pathogens that cause CAP include Streptococcus pneumoniae (penicillin-sensitive/resistant strains), Haemophilus influenzae (ampicillin-sensitive/resistant strains), Moraxella catarrhalis (all strains penicillin-resistant), S taphylococcus aureus, Group A streptococci, aerobic gram-negative bacteria (eg, Enterobacteriaceae such as Klebsiella spp or Escherichia coli) and microaerophilic bacteria and anaerobes. CAP is usually acquired via inhalation or aspiration of a pulmonary pathogen into a lung segment or lobe. However, in a large portion of the population, around 62%, no pathogen is detected despite extensive microbiologic evaluation. Overall, the most common causes are Streptococcus pneumoniae and respiratory viruses. A third category seen are respiratory viruses. A number of pathogens can give rise to CAP, generally categorized into typical and atypical pathogens.
0 Comments
Leave a Reply. |